{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:03:48Z","timestamp":1787501028074,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T00:00:00Z","timestamp":1476835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.mayocp.2016.10.009","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T23:47:00Z","timestamp":1485992820000},"page":"200-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis"],"prefix":"10.1016","volume":"92","author":[{"given":"Felicia","family":"Cosman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory C.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Valter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine A.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente Juel","family":"Riis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.mayocp.2016.10.009_bib1","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2016.10.009_bib2","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/jbmr.1698","article-title":"Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention","volume":"27","author":"Eisman","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"8","key":"10.1016\/j.mayocp.2016.10.009_bib3","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s00198-013-2348-z","article-title":"Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle","volume":"24","author":"\u00c5kesson","year":"2013","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.mayocp.2016.10.009_bib4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.mayocp.2016.10.009_bib5","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00198-004-1627-0","article-title":"An estimate of the worldwide prevalence, mortality and disability associated with hip fracture","volume":"15","author":"Johnell","year":"2004","journal-title":"Osteoporos Int"},{"issue":"10","key":"10.1016\/j.mayocp.2016.10.009_bib6","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1359\/jbmr.060711","article-title":"Association between prior non-spine non-hip fractures or prevalent radiographic vertebral deformities known to be at least 10 years old and incident hip fracture","volume":"21","author":"Schousboe","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.mayocp.2016.10.009_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.297.4.387","article-title":"Risk of subsequent fracture after low-trauma fracture in men and women","volume":"297","author":"Center","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2016.10.009_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2106\/JBJS.G.01529","article-title":"Proximal humeral fracture as a risk factor for subsequent hip fractures","volume":"91","author":"Clinton","year":"2009","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"7","key":"10.1016\/j.mayocp.2016.10.009_bib9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1359\/jbmr.090207","article-title":"Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001","volume":"24","author":"Ryg","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"issue":"6","key":"10.1016\/j.mayocp.2016.10.009_bib10","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/jbmr.35","article-title":"Time since prior fracture is a risk modifier for 10-year osteoporotic fractures","volume":"25","author":"Giangregorio","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.mayocp.2016.10.009_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11914-010-0023-2","article-title":"Timing of subsequent fractures after an initial fracture","volume":"8","author":"van Geel","year":"2010","journal-title":"Curr Osteoporos Rep"},{"issue":"12","key":"10.1016\/j.mayocp.2016.10.009_bib12","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?","volume":"99","author":"Cosman","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.mayocp.2016.10.009_bib13","unstructured":"Obaidi M, Chavira RE, Reinbolt L, Offman E, McKay K, O\u2019Dea LS. Pharmacokinetics and pharmacodynamics of subcutaneously (SC) administered doses of BA058, a bone mass density restoring agent, in healthy postmenopausal women. Paper presented at: American Association of Pharmaceutical Scientists (AAPS); November 10-14, 2010; New Orleans, LA. Abstract W5385."},{"issue":"12","key":"10.1016\/j.mayocp.2016.10.009_bib14","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrendo.2015.139","article-title":"PTH receptor-1 signaling-mechanistic insights and therapeutic prospects","volume":"11","author":"Cheloha","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.10.009_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.mayocp.2016.10.009_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.mayocp.2016.10.009_bib17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effects of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.mayocp.2016.10.009_bib18","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.mayocp.2016.10.009_bib19","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.mayocp.2016.10.009_bib20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jbmr.1854","article-title":"Goal-directed treatment of osteoporosis","volume":"28","author":"Cummings","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"issue":"6","key":"10.1016\/j.mayocp.2016.10.009_bib21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2016.10.009_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","article-title":"Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis","volume":"19","author":"Adami","year":"2008","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.mayocp.2016.10.009_bib23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"issue":"12","key":"10.1016\/j.mayocp.2016.10.009_bib24","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","article-title":"The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]","volume":"15","author":"Kurland","year":"2004","journal-title":"Osteoporos Int"},{"issue":"18","key":"10.1016\/j.mayocp.2016.10.009_bib25","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"issue":"9999","key":"10.1016\/j.mayocp.2016.10.009_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mayocp.2016.10.009_bib27","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mayocp.2016.10.009_bib28","article-title":"Multiple comparisons in drug clinical trials and preclinical assays: a-priori ordered hypothesis","author":"Maurer","year":"1995"},{"issue":"6","key":"10.1016\/j.mayocp.2016.10.009_bib29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/jbmr.5650110602","article-title":"Noninvasive assessment of bone mineral and structure: state of the art","volume":"11","author":"Genant","year":"1996","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.mayocp.2016.10.009_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s001980050223","article-title":"Intracapsular hip fracture: increased cortical remodeling in the thinned and porous anterior region of the femoral neck","volume":"10","author":"Bell","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.mayocp.2016.10.009_bib31","series-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","year":"2013"},{"issue":"24","key":"10.1016\/j.mayocp.2016.10.009_bib32","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocp.2016.10.009_bib33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"12","key":"10.1016\/j.mayocp.2016.10.009_bib34","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.mayocp.2016.10.009_bib35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.mayocp.2016.10.009_bib36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11914-014-0237-9","article-title":"Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches","volume":"12","author":"Cosman","year":"2014","journal-title":"Curr Osteoporos Rep"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616306309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616306309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T14:21:07Z","timestamp":1536070867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619616306309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0025619616306309"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.10.009","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}